Gait variability in Parkinson's disease: Influence of walking speed and dopaminergic treatment

Mon S. Bryant; Diana H. Rintala; Jyhgong G. Hou; Ann L. Charness; Angel L. Fernandez; Robert L. Collins; Jeff Baker; Eugene C. Lai; Elizabeth J. Protas

doi:10.1179/1743132811Y.0000000044

Gait variability in Parkinson's disease: Influence of walking speed and dopaminergic treatment

Mon S. Bryant, Diana H. Rintala, Jyhgong G. Hou, Ann L. Charness, Angel L. Fernandez, Robert L. Collins, Jeff Baker, Eugene C. Lai, Elizabeth J. Protas

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

Objectives: To study the effects of levodopa and walking speed on gait variability in individuals with Parkinson's disease (PD). Methods: Thirty-three individuals with PD were studied. Their mean age was 70.61±9.23 year. The average time since diagnosis was 9.65±5.80 year. Gait variability was studied while 'OFF' and 'ON' dopaminergic medication when the subjects walked at their usual and fastest speeds. Results: Variability of step time, double support time, stride length and stride velocity decreased significantly (P=0.037; P=0.037; P=0.022; P=0.043, respectively) after dopaminergic treatment. When subjects increased walking speed, the variability of stride length and stride velocity decreased significantly (P=0.038 and P=0.004, respectively) both while 'OFF' and 'ON' levodopa. Increasing walking speed did not change the variability of step time and double support time regardless of medication status. Conclusions: Levodopa decreased gait variability in persons with PD. Stride length and stride velocity variability appeared to be speed dependent parameters, whereas, the variability of step time and double support time appeared to be speed independent measures. Levodopa had positive effects on gait stability in PD.

Original language	English (US)
Pages (from-to)	959-964
Number of pages	6
Journal	Neurological Research
Volume	33
Issue number	9
DOIs	https://doi.org/10.1179/1743132811Y.0000000044
State	Published - Nov 2011

Keywords

Gait variability
Levodopa
Parkinson's disease
Walking speed

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1179/1743132811Y.0000000044

Cite this

@article{190ba162e40c42839b895c8d13df43aa,

title = "Gait variability in Parkinson's disease: Influence of walking speed and dopaminergic treatment",

abstract = "Objectives: To study the effects of levodopa and walking speed on gait variability in individuals with Parkinson's disease (PD). Methods: Thirty-three individuals with PD were studied. Their mean age was 70.61±9.23 year. The average time since diagnosis was 9.65±5.80 year. Gait variability was studied while 'OFF' and 'ON' dopaminergic medication when the subjects walked at their usual and fastest speeds. Results: Variability of step time, double support time, stride length and stride velocity decreased significantly (P=0.037; P=0.037; P=0.022; P=0.043, respectively) after dopaminergic treatment. When subjects increased walking speed, the variability of stride length and stride velocity decreased significantly (P=0.038 and P=0.004, respectively) both while 'OFF' and 'ON' levodopa. Increasing walking speed did not change the variability of step time and double support time regardless of medication status. Conclusions: Levodopa decreased gait variability in persons with PD. Stride length and stride velocity variability appeared to be speed dependent parameters, whereas, the variability of step time and double support time appeared to be speed independent measures. Levodopa had positive effects on gait stability in PD.",

keywords = "Gait variability, Levodopa, Parkinson's disease, Walking speed",

author = "Bryant, {Mon S.} and Rintala, {Diana H.} and Hou, {Jyhgong G.} and Charness, {Ann L.} and Fernandez, {Angel L.} and Collins, {Robert L.} and Jeff Baker and Lai, {Eugene C.} and Protas, {Elizabeth J.}",

note = "Funding Information: This work was supported by grants from the National Institutes of Health (RO1HL091153 [J. A. L{\'o}pez]) and R21HL098672 [D. W. Chung]) and the American Heart Association (AHA09GRNT2230070 [D. W. Chung]), and institutional funds from Puget Sound Blood Center.",

year = "2011",

month = nov,

doi = "10.1179/1743132811Y.0000000044",

language = "English (US)",

volume = "33",

pages = "959--964",

journal = "Neurological Research",

issn = "0161-6412",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

TY - JOUR

T1 - Gait variability in Parkinson's disease

T2 - Influence of walking speed and dopaminergic treatment

AU - Bryant, Mon S.

AU - Rintala, Diana H.

AU - Hou, Jyhgong G.

AU - Charness, Ann L.

AU - Fernandez, Angel L.

AU - Collins, Robert L.

AU - Baker, Jeff

AU - Lai, Eugene C.

AU - Protas, Elizabeth J.

N1 - Funding Information: This work was supported by grants from the National Institutes of Health (RO1HL091153 [J. A. López]) and R21HL098672 [D. W. Chung]) and the American Heart Association (AHA09GRNT2230070 [D. W. Chung]), and institutional funds from Puget Sound Blood Center.

PY - 2011/11

Y1 - 2011/11

N2 - Objectives: To study the effects of levodopa and walking speed on gait variability in individuals with Parkinson's disease (PD). Methods: Thirty-three individuals with PD were studied. Their mean age was 70.61±9.23 year. The average time since diagnosis was 9.65±5.80 year. Gait variability was studied while 'OFF' and 'ON' dopaminergic medication when the subjects walked at their usual and fastest speeds. Results: Variability of step time, double support time, stride length and stride velocity decreased significantly (P=0.037; P=0.037; P=0.022; P=0.043, respectively) after dopaminergic treatment. When subjects increased walking speed, the variability of stride length and stride velocity decreased significantly (P=0.038 and P=0.004, respectively) both while 'OFF' and 'ON' levodopa. Increasing walking speed did not change the variability of step time and double support time regardless of medication status. Conclusions: Levodopa decreased gait variability in persons with PD. Stride length and stride velocity variability appeared to be speed dependent parameters, whereas, the variability of step time and double support time appeared to be speed independent measures. Levodopa had positive effects on gait stability in PD.

AB - Objectives: To study the effects of levodopa and walking speed on gait variability in individuals with Parkinson's disease (PD). Methods: Thirty-three individuals with PD were studied. Their mean age was 70.61±9.23 year. The average time since diagnosis was 9.65±5.80 year. Gait variability was studied while 'OFF' and 'ON' dopaminergic medication when the subjects walked at their usual and fastest speeds. Results: Variability of step time, double support time, stride length and stride velocity decreased significantly (P=0.037; P=0.037; P=0.022; P=0.043, respectively) after dopaminergic treatment. When subjects increased walking speed, the variability of stride length and stride velocity decreased significantly (P=0.038 and P=0.004, respectively) both while 'OFF' and 'ON' levodopa. Increasing walking speed did not change the variability of step time and double support time regardless of medication status. Conclusions: Levodopa decreased gait variability in persons with PD. Stride length and stride velocity variability appeared to be speed dependent parameters, whereas, the variability of step time and double support time appeared to be speed independent measures. Levodopa had positive effects on gait stability in PD.

KW - Gait variability

KW - Levodopa

KW - Parkinson's disease

KW - Walking speed

UR - http://www.scopus.com/inward/record.url?scp=80855129489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855129489&partnerID=8YFLogxK

U2 - 10.1179/1743132811Y.0000000044

DO - 10.1179/1743132811Y.0000000044

M3 - Article

C2 - 22080998

AN - SCOPUS:80855129489

SN - 0161-6412

VL - 33

SP - 959

EP - 964

JO - Neurological Research

JF - Neurological Research

IS - 9

ER -

Gait variability in Parkinson's disease: Influence of walking speed and dopaminergic treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this